Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | fructose-bisphospatase II | 0.0356 | 0.5 | 0.5 |
Echinococcus multilocularis | fructose 1,6 bisphosphatase 1 | 0.0356 | 0.5 | 0.5 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.0356 | 0.5 | 0.5 |
Trypanosoma brucei | fructose-1,6-bisphosphatase | 0.0356 | 0.5 | 0.5 |
Schistosoma mansoni | fructose-16-bisphosphatase-related | 0.0356 | 0.5 | 0.5 |
Echinococcus granulosus | fructose 16 bisphosphatase 1 | 0.0356 | 0.5 | 0.5 |
Loa Loa (eye worm) | fructose-1,6-bisphosphatase | 0.0356 | 0.5 | 0.5 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.0356 | 0.5 | 0.5 |
Leishmania major | 0.0356 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
F (ADMET) | = 8.4 % | Oral bioavailability in Swiss albino mouse at 3 mg/kg | ChEMBL. | 25068800 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.